Bisphosphonate-related osteonecrosis of the jaws - Characteristics, risk factors, clinical features, localization and impact on oncological treatment

被引:172
|
作者
Otto, Sven [1 ]
Schreyer, Christian [1 ]
Hafner, Sigurd [1 ]
Mast, Gerson [1 ]
Ehrenfeld, Michael [1 ]
Stuerzenbaum, Stephen [2 ]
Pautke, Christoph [1 ]
机构
[1] Univ Munich, Dept Oral & Maxillofacial Surg, D-80337 Munich, Germany
[2] Kings Coll London, Analyt & Environm Sci Div, London SE1 9NH, England
基金
英国医学研究理事会;
关键词
Osteonecrosis of the jaw; Bisphosphonates; ONJ; BRONJ; Risk factors; Clinical features; Localization; PREVENTIVE MEASURES; MULTIPLE-MYELOMA; ZOLEDRONIC ACID; CANCER; BONE; IMPLEMENTATION; PAMIDRONATE; ALENDRONATE;
D O I
10.1016/j.jcms.2011.05.003
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: Osteonecrosis of the jaw (ONJ) is a serious side-effect of intravenous nitrogen-containing bisphosphonate therapy frequently used in the treatment of malignant diseases. Despite numerous case series published so far studies with detailed investigations into risk factors, the precise localization of ONJ and impact of ONJ on the oncological treatment remain sparse. Patients and methods: This single-centre study collated medical records (2003-2009) of all patients that suffered from ONJ within the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University of Munich, Germany. In total, 126 patients fulfilled the case criteria of ONJ and were examined clinically. The complete medical history including detailed questionnaires was collected of 66 patients, focussing in particular on the identification of underlying risk factors, clinical features, ONJ localization as well as the impact on the oncological treatment. Results: The majority of ONJ cases occurred in patients suffering from malignant diseases (n = 117; 92.8%), in particular breast cancer (n = 57; 45.2%), multiple myeloma (n = 37; 29.4%) and prostate cancer (n = 13; 10.3%), all received nitrogen-containing bisphosphonates intravenously. ONJ was also diagnosed in 9 patients (7.1%) suffering from osteoporosis or rheumatoid arthritis. The most prevalent clinical feature was exposed necrotic bone (93.9%) in the oral cavity which was accompanied in 78.8% of cases by pain. A predilection for the mandible and in particular for molar and premolar regions in both jaws was shown. Although no recommendation concerning the oncologic treatment was made, the manifestation of ONJ resulted (in a significant proportion of the patients) in a change of medication and schedule. The most frequent co-medications were steroids and anti-angiogenetic drugs, such as thalidomide. Discussion: The predilection for mandibular molar and premolar regions, and the infectious conditions that often precede the onset of ONJ support recent pathogenesis theories stating that local inflammation and associated pH-changes may trigger the release and activation of nitrogen-containing bisphosphonates ultimately resulting in necrosis. Conclusion: The development of ONJ has a multi-factorial aetiology and the clinical presentation can vary markedly. ONJ cannot only impair the quality of life but also the treatment of the underlying disease. (C) 2011 European Association for Cranio-Maxillo-Facial Surgery.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 50 条
  • [11] TREATMENT PROTOCOLS OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS Reply
    Wutzl, Arno
    Klug, Clemens
    Ewers, Rolf
    Millesi, Gabrielle
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2009, 31 (08): : 1113 - 1114
  • [12] Bisphosphonate-related osteonecrosis of the jaws (Bronj)
    Beninati, Francesco
    Pruneti, Riccardo
    Ficarra, Giuseppe
    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2013, 18 (05): : E752 - E758
  • [13] Intravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws
    Dodson, Thomas B.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 44 - 52
  • [14] Radiologic evaluation of bisphosphonate-related osteonecrosis of the jaws
    Ofluoglu, D.
    Koray, M.
    Ozer, N.
    Acikgoz, M. M.
    Tanyeri, H.
    ORAL DISEASES, 2010, 16 (06) : 552 - 552
  • [15] Nonexposed bisphosphonate-related osteonecrosis of the jaws: Another clinical variant?
    Junquera, Luis
    Gallego, Lorena
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2008, 66 (07) : 1516 - 1517
  • [16] The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws
    Muecke, Thomas
    Koerdt, Steffen
    Jung, Maximilian
    Mitchell, David A.
    Wolff, Klaus-Dietrich
    Kesting, Marco Rainer
    Loeffelbein, Denys John
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2016, 44 (04) : 369 - 373
  • [18] Bisphosphonate-Related Osteonecrosis of the Jaw: Clinical Features, Risk Factors, Management, and Treatment Outcomes of 26 Patients
    Thumbigere-Math, Vivek
    Sabino, Ma'Ann C.
    Gopalakrishnan, Rajaram
    Huckabay, Sabrina
    Dudek, Arkadiusz Z.
    Basu, Saonli
    Hughes, Pamela J.
    Michalowicz, Bryan S.
    Leach, Joseph W.
    Swenson, Karen K.
    Swift, James Q.
    Adkinson, Cheryl
    Basi, David L.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (09) : 1904 - 1913
  • [19] Utility of Hyperbaric Oxygen in Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws
    Freiberger, John J.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 96 - 106
  • [20] Imaging Findings in Bisphosphonate-Related Osteonecrosis of Jaws
    Arce, Kevin
    Assael, Leon A.
    Weissman, Jane L.
    Markiewicz, Michael K.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 75 - 84